Fatty liver disease (MASLD/MASH) trials in Argentina
8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- Where
- Buenos Aires, Ciudad Autónoma de Buenos Aires, La Plata, Ramos Mejía
- Age
- 18 years to 80 years
- People
- 1,650 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06215716 - Phase 3Taking peopleLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
- Where
- Buenos Aires, Ciudad Autonoma Buenos Aires, Pilar, Ramos Mejía, San Juan Bautista
- Age
- 18 years and over
- People
- 1,800 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00 - Phase 3Taking peopleLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Where
- Buenos Aires, Ciudad Autonoma Buenos Aires, Pilar, Ramos Mejía, San Juan Bautista
- Age
- 18 years and over
- People
- 1,590 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00 - Phase 3Taking peopleA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- Where
- Buenos Aires, CABA, Capital Federal, Córdoba, Pilar
- Age
- 18 years to 80 years
- People
- 1,350 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- Where
- Buenos Aires, CABA, Capital Federal, Córdoba, Pilar
- Age
- 18 years to 75 years
- People
- 1,800 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00 - Phase 3Taking peopleA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Where
- Buenos Aires, Ciudad Autónoma de Buenos Aires, La Plata, Ramos Mejía, Rosario
- Age
- 18 years to 80 years
- People
- 2,150 worldwide
- Run by
- Akero Therapeutics, Inc
See details and how to joinNCT06528314 - Phase 3Taking peopleA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Where
- ABB, Buenos Aires, Córdoba, Granadero Baigorria, Mar del Plata, Ramos Mejía, Rosario, Santa Fe
- Age
- 18 years and over
- People
- 4,500 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00 - No phaseNot yet taking people in ArgentinaFatty Liver and Pancreatic Steatosis
- Where
- Ciudad Autonoma de Buenos Aires
- Age
- 18 years to 65 years
- People
- 61
- Run by
- Maria Marta Piskorz
See details and how to joinNCT06757348